secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001193125-22-294309
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotech prioritizes pipeline, cuts 15% staff, halts SC187; maintains cash runway into 2025
--------------------------------------------------------------------------------

- Headcount reduced by ~15%; expects ~$7.9M in cash severance and ~$2.2M non-cash stock-based comp charges.
- Discontinues internal investment in SC187 (cardiomyocytes for heart failure) to focus on core programs.
- SC291 (CD19 CAR T) IND on track for 2022; initial clinical data expected in 2023.
- SC263 and SG295 INDs expected in 2023; SC451 and SC255 INDs in 2024.
- Cash runway extended into 2025; program timelines for lead programs not impacted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312522294309/0001193125-22-294309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312522294309/d191955d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-294309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer